Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma

Pratap Challa,1 Silke Schmidt,2 Yutao Liu,2 Xuejun Qin,2 Robin R. Vann,1 Pedro Gonzalez,1 R. Rand Allingham,1,2 Michael A. Hauser 1,2

(The first two authors contributed equally to this publication.)

1Department of Ophthalmology, Duke University Eye Center; 2Center for Human Genetics, Duke University Medical Center, Durham, NC

Purpose: To identify if recently described LOXL1 (lysyl oxidase-like 1) polymorphisms are associated with pseudoexfoliation glaucoma (XFG) in a United States (U.S.) Caucasian patient population.

Methods: Individuals with XFG were identified using standard clinical examination techniques. TaqMan allelic discrimination assays were used to genotype 13 single nucleotide polymorphisms (SNPs) that tag LOXL1 in Caucasian individuals. The coding region of exon 1 that includes the previously associated SNP, rs1048661, was sequenced. Allele and genotype frequencies were compared between cases and unrelated controls.

Results: Fifty affected individuals and 235 control individuals were recruited into this study. We replicated the previously reported association of three SNPs (rs1048661, rs2165241, and rs3825942) in our independent XFG population (single SNP p-values were 0.001-0.02). The risk alleles at these three and several other intragenic SNPs are part of an extended XFG-associated LOXL1 haplotype with a frequency of 32.0% in XFG patients and 21.6% in controls.

Conclusions: We have performed an analysis of LOXL1 and XFG in a United States patient population and have confirmed the strong association previously reported for Icelandic and Swedish samples. However, due to the high frequency of risk alleles in non-XFG individuals, this association should not form the basis of a diagnostic test for XFG. It is likely that additional genetic or environmental factors modulate the penetrance of LOXL1 susceptibility alleles.

Pseudoexfoliation syndrome (XFS) was initially described by Lindberg in 1917 [1] and further characterized by Vogt in 1925 [2]. It is a systemic disorder in which an unidentified, fibrillar substance is produced in abnormally high concentrations. The incidence of XFS varies among ethnic groups [3] with incidences of 20%-25% in the Scandinavian countries of Iceland and Finland [4] to 0% reported in Greenland Eskimos [5]. The Framingham Eye Study from the United States [6] revealed an overall incidence in non-glaucoma individuals of 0.6% at the age of 52–64 years that rose to 5.0% for 75–85-year-old individuals. Caucasians over 60 years old in the United States have an incidence of PEX around 1.6%-3% and African-Americans are approximately 0.4% [7,8].

Both Lindberg [1] and Vogt [2] noted the association of XFS with glaucoma and increasing age, and it is a major cause of glaucoma throughout the world [3,9,10]. In general, the incidence of glaucoma in XFS patients in the United States appears to vary with the individual’s ethnic background. The prevalence appears to be highest among individuals with Scandinavian ancestry and lower among African-Americans [8,11]. The reported prevalence of XFG varies among ethnic groups and ranges from 0.4%-28% of open angle glaucoma in the United States [8,11-13].

Recently, Thorleifsson et al. [14] performed a genome-wide association study and identified a strong association of XFG with three single nucleotide polymorphisms (SNPs) in the lysyl oxidase-like 1 gene (LOXL1). They identified one intronic SNP (rs2165241) and two nonsynonymous coding SNPs (rs3825942 and rs1048661) with significant disease association in Icelandic and Swedish individuals. This association was recently replicated in both the midwestern United States [15] and Australian [16] populations.

LOXL1 belongs to the “LOX” family of extracellular enzymes that have multiple functions including the cross-linking of collagen and elastin by oxidatively deaminating lysine residues. Since XFS deposits are associated with the extracellular and basement membrane regions, the LOX genes are legitimate functional candidates to be involved with XFG pathogenesis [17]. There are five such enzymes (LOX, LOXL1, LOXL2, LOXL3, and LOXL4) that are involved with extracellular matrix metabolism. LOXL1 has been implicated in the pathogenesis of spontaneous cervical artery dissection [18] as well as bladder cancer [19].

METHODS

Patient ascertainment: This study adhered to the tenets of the Declaration of Helsinki. The research protocol was approved
by the Duke University Institutional Review Board, and all patients consented to participating in the study. All patients were examined by board certified glaucoma specialists.

Pseudoexfoliation changes were identified as the presence of a central disk of XFS material, a clear annular zone (partial or complete), or flakes of XFS material on the lens surface, iris, or corneal endothelium in either eye. Patients were excluded if there was a history of exposure to intense infrared light, for example, glassblowing is associated with true exfoliation of the lens capsule rather than XFS. XFG was diagnosed when patients possessed the above XFS characteristics and at least two of the following criteria: A) documented intraocular pressure (IOP) ≥22 mmHg in either eye; B) glaucomatous optic nerve cupping defined as a cup to disc ratio >0.7 in either eye, notching of the neuroretinal rim, or an asymmetric cup to disc ratio >0.2; and/or C) glaucomatous visual field loss consistent with the optic nerve appearance. Glaucoma suspects were excluded from this study. All cases and controls were Caucasian. Controls were individuals of similar age as the patients without any evidence of pseudoexfoliation deposits on intraocular tissues. Their IOPs were in the normal range (<21 mmHg) with normal-appearing optic nerves.

**Single nucleotide polymorphism selection and genotyping methods:** Blood samples were obtained from each individual via peripheral venipuncture, and genomic DNA was isolated using standard techniques (Gentra, Minneapolis, MN). Tagging SNPs for Caucasian individuals were selected using Tagger in Haploview 3.32 with a pairwise r² threshold of 0.8, based on genotype data generated by the HapMap project. In addition to tagging SNPs, we also genotyped the three specific SNPs implicated by the previous study of XFG patients and controls [14]. See Figure 1 for LOXL1 gene structure and relative locations of SNPs used in this study. TaqMan allelic discrimination assays were performed for all SNPs per standard protocols from the manufacturer (Applied BioSystems, Foster City, CA). Two Centre d’Étude du Polymorphisme Humain (CEPH) standards were included in each 96-well plate for quality-control (QC), and samples from six individuals were duplicated across all plates with the laboratory technicians blinded to their identities. Genotype submission to the analysis database required matching QC controls (p>0.05). Table 1 presents the results of the logistic regression analysis and the linkage disequilibrium (LD) coefficients (r²) between each genotyped SNP and the previously implicated XFG susceptibility marker, rs3825942 (G153D). We confirmed the previously reported association between XFG and rs2165241 (p=0.001), rs1048661 (p=0.02), and rs3825942 (p=0.02). Due to inter-marker LD, several other intragenic SNPs also showed evidence of association at p<0.02. The haplotype analysis of SNPs, rs1048661 and rs3825942, confirmed that only three of the four possible haplotypes were observed in our sample (D’=1); the haplotype formed by the two protective alleles (T, A) was not detected. However, the frequency of the high-risk haplotype (G, G) in our population was lower than in the Icelandic and Swedish populations (United States: 69.9% in XFG cases, 46.6% in controls; Iceland: 81.4% in XFG cases, 49.8% in controls; and Sweden: 83.3% in XFG cases, 56.1% in controls). A haplotype analysis of all 12 SNPs with minor allele frequency (MAF)>5% confirmed that all individually associated SNPs (p<0.05 in Table 1) were part of the same XFG-associated haplotype, which had an estimated frequency of 21.6% in controls and 32.0% in XFG patients (haplotype-specific p-value was 0.03). All other LOXL1 haplotypes occurred at less than 10% frequency in controls. This is

**RESULTS**

Fifty XFG patients and 235 control individuals were recruited into this study. All patients (39 males-78% and 11 females-22%) and controls (145 males-61.7% and 90 females-38.3%) were Caucasian. The mean age of diagnosis was 74.0 (standard deviation,SD, was 8.0) years in patients; the age at recruitment was 64.9 (SD 11.6) years for the controls. All SNPs were in HWE in cases (p>0.05) and controls (p>0.05). Table 1 presents the results of the logistic regression analysis and the linkage disequilibrium (LD) coefficients (r²) between each genotyped SNP and the previously implicated XFG susceptibility marker, rs3825942 (G153D). We confirmed the previously reported association between XFG and rs2165241 (p=0.001), rs1048661 (p=0.02), and rs3825942 (p=0.02). Due to inter-marker LD, several other intragenic SNPs also showed evidence of association at p<0.02. The haplotype analysis of SNPs, rs1048661 and rs3825942, confirmed that only three of the four possible haplotypes were observed in our sample (D’=1); the haplotype formed by the two protective alleles (T, A) was not detected. However, the frequency of the high-risk haplotype (G, G) in our population was lower than in the Icelandic and Swedish populations (United States: 69.9% in XFG cases, 46.6% in controls; Iceland: 81.4% in XFG cases, 49.8% in controls; and Sweden: 83.3% in XFG cases, 56.1% in controls). A haplotype analysis of all 12 SNPs with minor allele frequency (MAF)>5% confirmed that all individually associated SNPs (p<0.05 in Table 1) were part of the same XFG-associated haplotype, which had an estimated frequency of 21.6% in controls and 32.0% in XFG patients (haplotype-specific p-value was 0.03). All other LOXL1 haplotypes occurred at less than 10% frequency in controls. This is

![LOXL1 gene structure with the position of each SNP as indicated.](image-url)
consistent with high pairwise D’ values between the coding SNP, rs3825942, and the other XFG-associated markers (D’>0.9) but relatively low r^2 values (Table 1) due to different allele frequencies.

The two coding SNPs, rs1048661 (R141L) and rs3825942 (G153D), were analyzed for their ability to predict affection status. The rs1048661 SNP demonstrated a 95.7% sensitivity (45 of 47 cases have the G allele) but only 13% specificity (28 of 215 controls lack the G allele) as a diagnostic test for XFG. The rs3825942 SNP demonstrated a 100% sensitivity (49 of 49 cases have the G allele) but only 3.1% specificity (7 of 225 controls lack the G allele).

**DISCUSSION**

Thorleifsson et al. [14] recently reported the results of a genome-wide association study of XFG that identified three strongly associated LOXL1 sequence variants, two of which were nonsynonymous coding SNPs. With this study, we have replicated these associations in a U.S. population of XFG patients and controls. However, we demonstrate that these associations are not strong enough to justify a diagnostic test for XFG. While the rs1048661 and rs3825942 SNPs individually have high sensitivity, their specificity is very poor (3.1% and 13.0%, respectively) due to their high prevalence in individuals without XFG. This same high prevalence of LOXL1 risk alleles has been reported in all populations examined to date: Nordic [14], midwestern United States [15], and Australian [16]. This suggests that additional genes or environmental factors affect the penetrance of these LOXL1 sequence variants. Further investigation of the complex etiology of XFG is warranted.

**ACKNOWLEDGMENTS**

Grant support was from: NIH K23 EY014019, core grant EY01894, R01 EY015543, R01 EY13315, and a Research to Prevent Blindness (RPB) Sybil B. Harrington Scholar Award.

**REFERENCES**

1. Tarkkanen A, Kivela T, John G. Lindberg and the discovery of exfoliation syndrome. Acta Ophthalmol Scand 2002; 80:151-4. [PMID: 11952480]
2. Vogt A. Ein neues Spaltlampenbild des Pupillengebietes: Hellblauer Pupillensaumfilz mit Hautchenbildung auf der Linsenvorderkapsel. Klin Monatsbl Augenheilkd 1925; 75:1-12.
3. Forsius H. Exfoliation syndrome in various ethnic populations. Acta Ophthalmol Suppl 1988; 184:71-85. [PMID: 2853925]
4. Forsius H. Prevalence of pseudoexfoliation of the lens in Finns, Lapps, Icelanders, Eskimos, and Russians. Trans Ophthalmol Soc U K 1979; 99:296-8. [PMID: 298430]
5. Lantukh VV, Piatin MM. Features of ocular pathology among the indigenous inhabitants of Chukotka. Vestn Oftalmol 1982; (4):18-20. [PMID: 7135721]
6. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24:335-610. [PMID: 7444756]
7. Mitchell P, Wang JJ, Hourihan F. The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study. Arch Ophthalmol 1999; 117:1319-24. [PMID: 10532440]
8. Cashwell LF Jr, Shields MB. Exfoliation syndrome. Prevalence in a southeastern United States population. Arch Ophthalmol 1988; 106:335-6. [PMID: 3345150]
9. Ringvold A. Epidemiology of glaucoma in northern Europe. Eur J Ophthalmol 1996; 6:26-9. [PMID: 8744847]
10. Tarkkanen AH. Exfoliation syndrome. Trans Ophthalmol Soc U K 1986; 105:233-6. [PMID: 3492068]
11. Ball SF. Exfoliation syndrome prevalence in the glaucoma population of South Louisiana. Acta Ophthalmol Suppl 1988; 184:93-8. [PMID: 2853928]
12. Ritch R. Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J Glaucoma 1994; 3:176-8.
13. Roth M, Epstein DL. Exfoliation syndrome. Am J Ophthalmol 1980; 89:477-81. [PMID: 7369310]
14. Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, Stefansson H, Jonsson T, Jonasdottir A, Jonasdottir A, Stefansdottir G, Masson G, Hardarson GA, Petursson H, Arnarsson A, Mottallebipour M, Wallerman O, Wadelius C, Gulcher JR, Thorsteinsdottir U, Kong A, Jonasson F, Stefansson K. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007; 317:1397-400. [PMID: 17690259]
15. Fingert JH, Alward WL, Kwon YH, Wang K, Streb LM, Sheffield VC, Stone EM. LOXL1 Mutations Are Associated with Exfoliation Syndrome in Patients from the Midwestern United States. Am J Ophthalmol 2007; 144:974-5. [PMID: 18036875]
16. Hewitt AW, Sharma S, Burdon KP, Wang JJ, Baird PN, Dimasi DP, Mackey DA, Mitchell P, Craig JE. Ancestral LOXL1 variants are associated with pseudoxfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. Hum Mol Genet 2007; [Epub ahead of print].
17. Ovodenko B, Rostagno A, Neubert TA, Shetty V, Thomas S, Yang A, Liebmann J, Ghiso J, Ritch R. Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci 2007; 48:1447-57. [PMID: 17389470]
18. Kuhlenbaumer G, Friedricks F, Kis B, Berger P, Maintz D, Nassenstein I, Nabavi D, Dittrich R, Stoll M, Ringelstein B. Association between single nucleotide polymorphisms in the lysyl oxidase-like 1 gene and spontaneous cervical artery dissection. Cerebrovasc Dis 2007; 24:343-8. [PMID: 17690546]
19. Wu G, Guo Z, Chang X, Kim MS, Nagpal JK, Liu J, Maki JM, Kivirikko KI, Ethier SP, Trink B, Sidransky D. LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res 2007; 67:4123-9. [PMID: 17456585]
20. Weir BS. Genetic data analysis II. 1996, Sunderland (MA): Sinauer Associates Inc; 1996.
21. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55:56-65. [PMID: 12890927]
22. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-34. [PMID: 11791212]